Danaher Q2 Results Cut Revenue Outlook

Danaher reported second-quarter 2026 results on July 21, beating estimates and raising full-year adjusted EPS guidance while cutting its core revenue-growth outlook and flagging weaker biotechnology sales and shipment timing that will push some revenue into 2027.

Quarter Results and Cash Flow

Danaher said revenue for the quarter ended June 26 was $6.3 billion, up 5.5% year-over-year. Net earnings were $870 million, or $1.23 per diluted share, and adjusted non-GAAP diluted EPS was $1.94, exceeding consensus. Operating cash flow reached about $1.5 billion, with non-GAAP free cash flow near $1.3 billion. President and CEO Rainer M. Blair said, "We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth."

Life Sciences delivered its strongest quarter in several years and, along with Diagnostics, led core sales gains. Diagnostics showed margin pressure related to integrating recent acquisitions. Reported growth included roughly 1.5 percentage points from acquisitions and about 1.0 point from favorable foreign exchange, with the remainder from core sales.

Outlook and Bioprocessing Timing

Danaher raised full-year adjusted EPS guidance to $8.45–$8.60, attributing the modest increase mainly to the earlier-than-anticipated Masimo acquisition closing and productivity gains. The company lowered its full-year core revenue growth forecast to 3–4% and expects roughly 2–3% core growth in the third quarter, citing normalization in respiratory testing and customer project timing in bioprocessing as headwinds.

Biotechnology revenue for the quarter was about $1.92 billion, below external expectations. Management said some large bioprocessing shipments were delayed into 2027, even as bioprocessing orders grew in the mid-teens, indicating strong underlying demand but near-term timing risks.

Masimo’s earlier closing was a key factor enabling the EPS guidance raise and was described as immediately accretive to adjusted EPS. Acquisitions, primarily Masimo, contributed about four percentage points to Diagnostics revenue growth in the quarter.

High-growth emerging markets rose about 15% year-over-year, accounted for roughly 31% of total sales, and showed core sales growth above 10%. Developed markets were flat to slightly down on a core basis.

Management reiterated expectations to exit 2026 with mid-single-digit core revenue growth. Danaher Business System productivity and integration benefits are expected to support margins and EPS despite modest top-line growth. Life Sciences is projected to remain the primary growth driver through the rest of the year.